Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of sintilimab for advanced malignant tumors
ChiCTR2000040663Phase 4Not yet recruiting
- Sponsor
- Yanshi People's Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more, sponsored by Yanshi People's Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040663.